Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002986 (Fabry)
 5,646 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In adults, elevated transaminases and hepatomegaly, often mild, with moderate to massive idiopathic splenomegaly might hint to a lysosomal storage disease (LSD). In most of these cases, hepatosplenomegaly does not eventually lead to cirrhosis, hepatocellular carcinoma or cholestasis. Nevertheless, the hepatic clinical findings might be the incentive for the patient to present at the physician's office. Many of the currently known >50 lysosomal storage diseases might manifest in liver: out of these, the most important ones in adults are: Gaucher disease, cholesterol ester storage disease (CESD) and the Niemann-Pick diseases. An increase of plasma chitotriosidase should alert the physician for the presence of an LSD. For Gaucher's disease, enzyme supplementation and substrate deprivation constitute effective therapeutic options. Fabry's disease, the most prevalent lysosomal storage disease, does usually not affect the liver, but causes painful episodes of hands' or feet pain (acroparesthesias), left ventricular hypertrophy, renal failure, early stroke and decreased life expectancy. The emerging advent of effective therapeutic options and the cumulative prevalence of lysosomal storage diseases urge the hepatologist to add these diagnostic pathways to the clinical repertoire.
Best Pract Res Clin Gastroenterol 2010 Oct
PMID:Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. 2095 64

Fabry disease is induced by a mutation in the alpha-galactosidase A gene, causing a deficiency of the enzyme alpha-galactosidase A. (1) The enzyme defect leads to progressive intracellular accumulation of globotriaosylceramide in lysosomes of various tissues and organs, including heart, kidney and nerve system. Cardiac involvement is common and is presenting as concentric left ventricular hypertrophy. Myocardial replacement fibrosis is a typical feature of more advanced stages of Fabry cardiomyopathy, first limited to the mid-myocardial layers of the basal postero-lateral wall, then spreading to transmural fibrosis. Since 2001, enzyme replacement therapy is available. If therapy is started early, before myocardial fibrosis has developed, a long-term improvement of myocardial morphology, function and exercise capacity can be achieved. In end-stage cardiomyopathy enzyme replacement therapy might prevent further progression of the disease. This review provides an overview of Fabry disease, with a focus on cardiac involvement with its characteristic features, clinical presentation and possible treatment.
Best Pract Res Clin Endocrinol Metab 2015 Mar
PMID:Fabry disease and the heart. 2598 73

Enzyme replacement therapies have been developed and authorized for commercial use for six different lysosomal storage disorders. For Gaucher disease, Fabry disease and mucopolysaccharidosis type 1, disease-specific treatments have been available for more than a decade. Although long term follow-up data are still sparse, therapeutic goals for patients with Gaucher disease and Fabry disease have been formulated and published for both adults and children. Without adaptation or modification, these goals are often applied in clinical research and in routine patient care across the entire phenotypic spectrum of disease, although in practice, patients commonly manifest high variability in clinical presentation and course of the illness. In this context, establishing goals for the follow-up and treatment of late onset/attenuated phenotypes is particularly challenging. In this chapter, we review current therapeutic goals for Gaucher disease and Fabry disease and discuss approaches for those with attenuated disease manifestations.
Best Pract Res Clin Endocrinol Metab 2015 Mar
PMID:The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. 2598 74

Powdered infant formula (PIF) is a worldwide, industrially produced, human milk substitute. Manufacture of PIF faces strict quality controls in order to ensure that the product meets all compositional requirements. Near-infrared (NIR) spectroscopy is a rapid, non-destructive and well-qualified technique for food quality assessments. The use of fibre-optic NIR sensors allows measuring in-line and at real-time, and can record spectra from different stages of the process. The non-contact character of fibre-optic sensors can be enhanced by fitting collimators, which allow operation at various distances. The system, based on a Fabry-Perot interferometer, records four spectra concurrently, rather than consecutively as in the "quasi-simultaneous" multipoint NIR systems. In the present study, a novel multipoint NIR spectroscopy system equipped with four fibre-optic probes with collimators was assessed to determine carbohydrate and protein contents of PIF samples under static and motion conditions (0.02, 0.15 and 0.30m/s) to simulate possible industrial scenarios. Best results were obtained under static conditions providing a R(2) of calibration of 0.95 and RMSEP values of 1.89%. Yet, considerably low values of RMSEP, for instance 2.70% at 0.15m/s, were provided with the in-motion predictions, demonstrating the system's potential for in/on-line applications at various levels of speed. The current work also evaluated the viability of using general off-line calibrations developed under static conditions for on/in-line applications subject to motion. To this end, calibrations in both modes were developed and compared. Best results were obtained with specific calibrations; however, reasonably accurate models were obtained with the general calibration. Furthermore, this work illustrated independency of the collimator-probe setup by characterizing PIF samples simultaneously recorded according to their carbohydrate content, even when measured under different conditions. Therefore, the improved multipoint NIR approach constitutes a potential in/on-line tool for quality evaluation of PIF over the manufacturing process.
 ...
PMID:Multipoint NIR spectroscopy for gross composition analysis of powdered infant formula under various motion conditions. 2715 95